



The Association of Red Blood Cell Distribution Width with Secondary Infection and Prognosis in hospitalized patients with COVID -19 pneumonia

Neda Saeedian¹, Mohsen Seddigh-Shamsi², Shima Nabavi³, Zahra Javidarabshahi⁴, Farnoosh Ebrahimzadeh³, Sahar Ravanshad⁶, Mina Akbarirad³, Shohre Khatami³, Maryam Emadzadeh⁵, Shaghayegh Badriahmadi¹, Mahnaz Mozdourian^{4*}

¹ Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

²Department of Hematology- Oncology, Mashhad University of Medical Science, Mashhad, Iran.

³MD-Internist, Department Of Internal Medicine, Mashhad University of Medical Science, Mashhad, Iran.

⁴ Pulmonologist, Lung Diseases Research Center, Mashhad University of Medical Science, Mashhad, Iran.

⁵ Community Medicine Specialist, Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

⁶ Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

ARTICLE INFO

Article type:
Original article

Article history:
Received: 06 Feb 2021
Revised: 07 March 2021
Accepted: 14 March 2021

Keywords:
Coronavirus Disease-19
Prognosis
Secondary Infection
Red Blood Cell Distribution
Width

ABSTRACT

Introduction: Novel Coronavirus outbreak has posed a global threat. While the infection appears to be mild in most patients, considering its high rate of transmission, a large number of people are at risk of developing severe to critical illness in total which makes prognosis studies a priority. The aim of the present study was to evaluate red blood cell distribution width (RDW) as a predictive factor for diagnosing severe cases of coronavirus disease 2019 (COVID-19).

Materials and Methods: A total number of 204 inpatients diagnosed with COVID-19 including 122 men and 82 women (Mean age: 58.83±15.93 years old) treated at Imam Reza Hospital, Mashhad, Iran were included in the study. Patients were divided into severe and moderate groups according to their clinical signs and examinations and pulmonary imaging features. Demographic Data, laboratory test results, treatments, patients' complications and outcome were recorded. Mann-Whitney U test and spearman correlation coefficient (r) were performed to assess RDW correlation with severity and serious complications in patients including intensive care unit (ICU) admission, shock, secondary infections, intubation, length of hospitalization and death. Receiver operating characteristics (ROC) curves analysis was carried out to define the reliability of RDW as a predictive indicator in severe COVID-19.

Results: The results showed statistical significant correlations between high levels of RDW and developing secondary infections and longer hospitalization (P values ≤0.001). The optimal cutoff for RDW to predict the length of hospitalization (≤ 7 days or more than 7 days) was estimated to be 14.65% with 94% sensitivity and 71.3% specificity. The area under curve was calculated to be 0.895 through Roc curve analysis.

Conclusion: High predictive value of RDW, a routine blood test parameter, could be used in diagnosing COVID-19 patients at higher risk for developing secondary infections and longer hospital stay which in turn helps with better management of the disease.

► Saeedian, N., SeddighShamsi, M., Nabavi, S., Javidarabshahi, Z., Ebrahimzadeh, F., Ravanshad, S., AkbariRad, M., Khatami, S., Emadzadeh, M., Badriahmadi Sh, Mozdourian, M. The Association of Red Blood Cell Distribution Width with Secondary Infection and Prognosis in hospitalized patients with COVID -19 pneumonia. *J Cardiothorac Med.* 2021; 9(1): 755-761.

*Corresponding author: MahnazMozdourian, Lung Diseases Research Center, Mashhad University of Medical Science, Mashhad, Iran. Tel & Fax: +985138598818, Email: mozdorianmh@mums.ac.ir

© 2016 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Coronaviruses are a large family of viruses identified in the mid-1960s and are known to cause multiple system infections in numerous animals and also infect humans with common colds and serious respiratory tract illnesses (1-4). Two outbreaks of coronaviruses in humans have occurred since 2002; SARS-CoV (2002) causing Severe Acute Respiratory Syndrome (SARS) and MERS-CoV (2012) causing Middle East Respiratory Syndrome (MERS) (2, 5, 6).

In December 2019, an outbreak of pneumonia cases of unknown a etiology, referred to as Novel Coronavirus Pneumonia (NCP) (later named as Coronavirus Disease 2019 (COVID-19) by WHO), was reported in Wuhan, Hubei Province, China and rapidly spread elsewhere (7). Genetic analysis of the novel coronavirus (2019-nCoV) revealed a great deal of similarity (88%) to SARS-CoV, suggesting that they are closely related and (4, 8, 9) finally led to designating it as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (10, 11). Since Then, a surge of new cases infected with (SARS-CoV-2) has been reported throughout the world (4, 12) which immediately became a serious public health problem globally (13). While the outbreak initially originated from a zoonotic transmission (14), soon the ability of human-to-human transmission became evident (15). The rapid transmission (median $R_0 \approx 3.0$) (16) led to a world-wide emergency. The total number of laboratory-confirmed cases has exceeded 1,991,562 with over 130,885 Deaths as of Apr 16, 2020 (17).

Patients' common symptoms mainly include fever, cough, dyspnea and myalgia or fatigue (4, 7, 18). Most patients infected with SARS-CoV-2 experience a mild clinical course. However, Severe cases are often in urgent need of intensive medical resources as they progress rapidly (particularly within 7-14 days from onset of symptoms) (15) to acute respiratory distress syndrome (ARDS) leading to acute respiratory failure, metabolic acidosis, coagulopathy, and septic shock with high mortality rates in a short time (20 times higher than that of non-severe COVID-19 patients) (19, 20). This situation denotes the necessity of prognosis assessments. Early identification of risk factors to prognoses and recognize the

COVID-19 patients at high risk for developing serious complications among the infected crowds using clinical data is an urgent yet demanding mission. It could help with providing critically ill cases with early treatment, facilitating proper supportive care and immediate access to the intensive care unit (ICU) if necessary and reducing unnecessary or inappropriate health care utilization through screening and prioritizing patients, all of which lead to a potential decrease in mortality (13, 19, 20).

Red blood cell distribution width (RDW), a hematological indicator, could reflect subclinical inflammation (21) and has been recently regarded as a powerful prognostic biomarker in a variety of disorders such as cardiovascular diseases (22), acute and chronic kidney diseases (23), diabetes (24), cancer (25), chronic obstructive pulmonary diseases (COPD) (26), ARDS (27), hepatic fibrosis and necro inflammation (28, 29) and critically ill patients (30). The increase of RDW level in the abovementioned conditions is reported to be an independent risk factor for severe morbidity and increased mortality (30). So far, not enough prognostic studies have been carried out regarding predicting severity in COVID-19 patients. Considering RDW high predictive value in various disorders, the present study was carried out to investigate RDW potential as a prognostic factor for COVID-19 patients at high risk for developing severe illness.

Materials and Methods

Patients

A total number of 204 adult inpatients (≥ 18 years old) diagnosed with COVID-19 who were referred to Imam Reza Hospital, the main center for COVID-19 patients in Mashhad, Iran during 14-20 March 2020 were included in this study. Patients younger than 18 and those with hematologic malignancies or those having undergone a recent chemotherapy were excluded from the study. The following diagnostic criteria were applied according to the recent guidelines about COVID-19. Clinical Symptoms including fever, myalgia or fatigue, respiratory symptoms such as cough and dyspnea, laboratory test results; elevated C-reactive protein (CRP), leukopenia or lymphopenia, and typical

imaging features in the chest computed tomographic scans (CT scan). Diagnosis was ultimately confirmed if the RNA of SARS-CoV-2 was found in the patients' nasopharyngeal swab samples using real-time reverse transcription-polymerase chain reaction (RT-PCR). Patients were divided into two groups (severe and moderate) based on clinical features. Severe cases were identified as patients with respiratory rate (RR) >30 times/min and or oxygen saturation (SpO₂) $\leq 93\%$ at rest on room air, while others were classified as moderate. Cases were also categorized into severe and non-severe groups considering the features in their lung CT scan, in which involvements of three lobes were defined as severe and two lobes involvement were considered non-severe. This research was approved by the Ethics Committee of Mashhad University of Medical Sciences. All the patients were fully informed about the study and signed the written consent.

Data Collection:

Demographic data, past medical history, signs and symptoms were recorded for each patient and clinical laboratory test findings including complete blood count with differential (CBC with diff), C-reactive protein (CRP) and other tests and also Lung CT scans were achieved through routine clinical practice. Treatments, length of hospitalization, outcome data, course of the disease such as being admitted to ICU, being intubated, going into shock and being affected by secondary infections were precisely monitored and recorded in detail for all the participants. All the patients received either Hydroxychloroquine and or Lopinavir/Ritonavir (Kaletra) as antiviral. Empiric antibiotic therapy including Ceftriaxone and azithromycin were prescribed and were substituted by other antibiotics if secondary infections were suspected.

Statistical Analysis:

Analyzes were performed using SPSS software (Version 26.0, SPSS, Inc., Chicago, IL, USA). Frequency and percent were used to report categorical variables while mean and standard deviation were tools to present the continuous variables such as age, length of hospitalization and RDW levels. Spearman correlation coefficient (r) was used to

compare RDW levels in different lengths of hospitalization (an indicator of severe illness in this study). Correlation analysis between categorical variables indicating severe illness (Hospitalization more than 7 days, ICU admission, intubation, shock, secondary infection, radiologic and clinical severity and death) and RDW levels were carried out using Mann-Whitney U Test. Correlations were considered statistically significant where P values were less than 0.05. The usefulness of RDW to predict severity in COVID-19 patients, its optimal cutoff, sensitivity and specificity were assessed through receiver operating characteristics (ROC) curves analysis.

Results

Among the total number of 204 patients diagnosed with COVID-19 including 122 (59.8%) men and 82 (40.2%) women with the mean age of 58.83 ± 15.93 years old. The frequency and percentage of the COVID-19 patients' gender and comorbidities have been presented in table1, that shows diabetes mellitus (62 patients) and Hypertension (60 patients) as the most prevalent diseases respectively (30.4% and 29.4%). Out of the 204 COVID-19 patients of this study, 33 (16.2%) were considered moderate and 167 patients (81.8%) developed severe to critical illness having one or both of the above mentioned criteria (RR >30 times/min, SpO₂ $\leq 93\%$). Moreover, 145 patients (71.1%) were considered severe in terms of lung CT scan features, having three lobes of the lung involved, while the other 59 patients (28.9%) had only 2 lobes involved. In total, 67 patients (33%) were hospitalized for more than 7 days; while 115 patients (56%) had shorter hospital stay (equal or less than 7 days) (Information regarding 22 cases (11%) was missed). The minimum and maximum days of hospitalization were 1 and 22 days respectively, with 7.19 ± 3.67 days as the average hospital stay. Fourteen patients (6.9%) needed intensive medical care and were transferred to (ICU). Intubation was applied in 23 cases (11.3%), 7 patients (3.4%) went into shock and 83 patients (40.7%) developed secondary infections. Among all, 22 patients (10.8%) died during the period of observation while others were discharged.

Table1. Demographic Characteristics of COVID-19 patients

Demographic Characteristics		Frequency	Percent
Gender	Male	122	59.8%
	Female	82	40.2%
Medical History	Diabetes mellitus	62	30.4%
	Ischemic Heart Disease	36	17.6%
	Hypertension	60	29.4%
	Asthma	6	2.9%
	Autoimmune diseases	5	2.5%
	Chronic kidney disease	3	1.5%
	Transplantation	1	0.5%
	COPD ^a	16	7.8%
	Cerebrovascular disease	3	1.5%
	CNS ^b diseases	2	1%
	Gastrointestinal diseases	204	100%
	Hepatitis	1	0.5%
	Hypothyroidism	3	1.5%
Malignancy	8	3.9%	

a. Chronic Obstructive Pulmonary Disease, b. Central nervous system

Variables	Frequency	Percent	RDW (Mean) %	P Value*	
Length of Hospitalization	115	≤ 7 days ^c	56%	13.86 ± 1.40	≤0.001
	67	> 7 days ^d	33%	16.50 ± 1.68	
	22	Missing ^e	11%		
ICU	No	190	93.1%	14.82 ± 1.95	0.472
	Yes	14	6.9%	14.52 ± 2.28	
Intubation	No	181	88.7%	14.87 ± 2.01	0.262
	Yes	23	11.3%	14.27 ± 1.59	
Shock	No	197	96.6%	14.85 ± 1.99	0.129
	Yes	7	3.4%	13.64 ± 0.94	
Clinical Severity	Moderate	33	16.2%	14.34 ± 1.83	0.153
	Sever/critical	139+28	81.8%	14.90 ± 1.99	
	Missing ^e	4	2%		
Secondary Infections	No	121	59.3%	14.37 ± 1.76	≤0.001
	Yes	83	40.7%	15.41 ± 2.10	
Radiologic Severity	Moderate ^a	59	28.9%	14.72 ± 1.99	0.798
	Severe ^b	145	71.1%	14.83 ± 1.97	
Death	No	182	89.2%	14.88 ± 2.00	0.159
	Yes	22	10.8%	14.14 ± 1.53	
Total	204		14.80 ± 1.97		

a. Two lobes of lung were involved, b. Three lobes of lung were involved, c. Hospitalization equal or less than 7 days, d. Hospitalization more than 7 days, e. Missed data, * P values calculated by Mann-Whitney U Test.

To investigate the prognostic value of RDW, correlation studies were carried out to compare RDW levels in different groups of variables. Table 2 shows RDW levels (mean) in different variables and the p values calculated for each analysis. The average level of RDW was 14.80% ± 1.97 ranging from 11.70% to 20%. It showed a higher average in people categorized in the severe

group compared to the moderate ones both in terms of clinical examination and imaging features, however no statistically significant difference was observed. There were no statistical significant correlation between RDW level and death, ICU, intubation and shock. However, a significant relationship was observed between RDW and secondary infections and the length of hospitalization in

which higher levels of RDW were correlated with longer hospitalization (Spearman Correlation Test- P value \leq 0.001) and getting secondary infections (Mann-Whitney U Test - P values \leq 0.001). Moreover, in average, the highest RDW (15.41% \pm 2.10) was associated with patients who ultimately got secondary infections among all the categories studied in this research.

The efficiency of RDW as a marker to predict hospital stay (more than 7 days/equal or less than 7 days) was evaluated using Roc curves (Shown in Figure 1). The area under curve (AUC) was 0.895 and the optimal cutoff of RDW was estimated to be 14.65% with sensitivity and specificity of 94% and 71.3%, respectively.




Figure1. Roc analysis of RDW

Discussion

In this study we assessed the prognostic value of RDW in early prediction of secondary infection in COVID-19 patients. Diagnosing COVID-19 patients at higher risk for developing severe illness is of great importance since it could effectively serve the purpose of better managing the patients, providing optimal treatment as soon as possible and preventing from wasting medical resources in coronavirus outbreak, all in turn contribute to a reduction in mortality rate. Few studies have been carried out to design a model for early prediction of severe cases of COVID-19. Feng et al. (2020) reported CT severity and neutrophil-to-lymphocyte ratio (NLR) as independent risk factors for short-term

progression of COVID-19 (15) which was in accordance with the study done by Liu et al. (2020) also reporting NLR as a risk factor for severe COVID-19 (20). Gong et al. (2020) emphasized on the role of RDW in predicting severity in COVID-19 among all 7 indicators (age, serum lactate dehydrogenase, CRP, RDW, blood urea nitrogen, albumin, direct bilirubin) they found to be associated with severe COVID-19 (19). Red cell distribution width (RDW), the indicator of variation in the size of red blood cells (RBC), has been regarded as a useful predictive index for numerous disorders. It is a routine laboratory parameter which is reported as a part of a standard complete blood count (CBC) and the cost of measuring it is low enough to be extensively used (31).

The results of the present study suggest that higher RDW on admission is statistically correlated with higher occurrence of secondary infections and longer hospitalization. Moreover, RDW was estimated to be a reliable tool to predict the length of hospital stay according to Roc curve analysis which made it possible to define the optimal cutoff (14.65%) for RDW with high sensitivity and specificity, suggesting that COVID-19 patients with RDW levels higher than 14.65% on admission are more likely to be hospitalized for more than 7 days. Therefore, it seems that this easy and economical tool, RDW, could independently predict the development of a secondary infection in coming days and also the length of hospitalization which seems to be the inevitable consequence of secondary infections.

In the present study, 40.7% of the patients showed secondary infection which is the most prevalent complication among the several factors associated with severity in COVID-19 patients investigated in this research. This might be due to the reason that secondary infection itself could lead to other serious conditions such as septic shock, requiring intubation and ICU admission. In the study done by Zhou et al. (2020), 112 patients (59%) out of the total number of 191, suffered from sepsis which was the most common complication. Secondary infections were observed in 28 (15%) patients, among whom 27 died, consisting 50% of the non-survivors'

population (54 death) (14). The high prevalence of secondary infections in patients with severe COVID-19 and its contribution to other severities make it an especially important and useful factor to be predicted. Early prediction of secondary infections could help with more efficient decisions regarding treatment course including prescription of broad spectrum antibiotics (e.g. Vancomycin + Meropenem instead of Ceftriaxone) at the first days of admission to prevent from development of the infection and longer hospitalization, considering more specific patients isolation measures and being prepared for providing other appropriate medical care. Accordingly, RDW, particularly levels higher than 14.65%, could work as an efficient alarm, revealing a latent infection and severity in patients with COVID-19. The increased inflammatory response could probably explain the reason of increase in RDW in severe COVID-19. Inflammatory reactions affect bone marrow function. Some pro-inflammatory cytokines inhibit erythrocyte maturation, resulting in immature red blood cells entering the bloodstream and increasing RDW (31, 32). Therefore, a hidden infection could be the underlying reason of significance increase in RDW in severe cases of COVID-19.

Conclusion

In conclusion, early prediction of severity in COVID-19 is of great clinical importance which could considerably improve the health care and prevent from wasting medical resources in the critical situation resulted from the SARS-Cov-2 outbreak. RDW is suggested to be a valuable prognostic factor for prediction of secondary infections, length of hospitalization and severity in COVID-19 patients which is both inexpensive and easy to measure in routine blood tests. However, more studies on wider populations of patients are needed to be done to determine a more precise cutoff for this index.

Conflicts of interest

The authors have no competing interest.

References

1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018;23(2):130-7.
2. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of

a novel coronavirus in patients with severe acute respiratory syndrome. *New England journal of medicine*. 2003;348(20):1967-76.

3. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of Medicine*. 2012;367(19):1814-20.
4. Attaran, D., Ataei Azimi, S., M.Lari, S., Rokni, H., Taghavi, M., Maraashi, M. The Evaluation of Pulmonary Function Tests in Patients with Polycystic Ovary Syndrome. *Journal of Cardio-Thoracic Medicine*, 2013; 1(3): 84-88
5. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, Van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *The Lancet*. 2003;362(9380):263-70.
6. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *Journal of virology*. 2013;87(14):7790-2.
7. Qu R, Ling Y, Zhang Yh, Wei Ly, Chen X, Li X, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease-19. *Journal of Medical Virology*. 2020.
8. Beigoli S, Sharifi Rad A, Askari A, Assaran Darban R, Chamani J. Isothermal titration calorimetry and stopped flow circular dichroism investigations of the interaction between lomefloxacin and human serum albumin in the presence of amino acids. 2019;37(9):2265-2282.
9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*. 2020;395(10224):565-74.
10. Phelan A, Katz R, Gostin L. The novel coronavirus originating in wuhan. China, *J Am Med Assoc*. 2020.
11. Gorbalenya A, Baker S, Baric R. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the coronavirus study group. *bioRxiv preprint first posted online February 11, 2020*. 2020:2020.2002.2007.937862. doi: 10.1101/2020.02.07.937862. Accessed February. 2020;12.
12. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *New England Journal of Medicine*. 2020.
13. Chamani j. Energetic domains analysis of bovine α -lactalbumin upon interaction with copper and dodecyl trimethylammonium bromide. *Journal of Molecular Structure*. 2010;979(1-3):227-234.

14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020.
15. Feng Z, Yu Q, Yao S, Luo L, Duan J, Yan Z, et al. Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics. *medRxiv*. 2020.
16. Guan W-j, Chen R-c, Zhong N-s. Strategies for the prevention and management of coronavirus disease 2019. *Eur Respiratory Soc*; 2020.
17. Coronavirus disease 2019 (COVID-19) Situation Report – 87 2020 [Available from: <https://www.who.int/>]
18. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *MedRxiv*. 2020.
19. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe 2019-Novel Coronavirus Pneumonia (COVID-19): A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. *medRxiv*. 2020.
20. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. *MedRxiv*. 2020.
21. de Gonzalo-Calvo D, de Luxán-Delgado B, Rodríguez-González S, García-Macia M, Suárez FM, Solano JJ, et al. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. *Cytokine*. 2012;58(2):193-8.
22. Arbel Y, Weitzman D, Raz R, Steinvil A, Zeltser D, Berliner S, et al. Red blood cell distribution width and the risk of cardiovascular morbidity and all-cause mortality. *Thrombosis and haemostasis*. 2014;112(02):300-7.
23. Oh HJ, Park JT, Kim J-K, Yoo DE, Kim SJ, Han SH, et al. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. *Nephrology Dialysis Transplantation*. 2012;27(2):589-94.
24. Engström G, Smith J, Persson M, Nilsson P, Melander O, Hedblad B. Red cell distribution width, haemoglobin A 1c and incidence of diabetes mellitus. *Journal of internal medicine*. 2014;276(2):174-83.
25. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. *PloS one*. 2013;8(11).
26. Ozgul G, Seyhan EC, Ozgul MA, Gunluoglu MZ. Red blood cell distribution width in patients with chronic obstructive pulmonary disease and healthy subjects. *Archivos de Bronconeumologia (English Edition)*. 2017;53(3):107-13.
27. Wang B, Gong Y, Ying B, Cheng B. Relation between red cell distribution width and mortality in critically ill patients with acute respiratory distress syndrome. *BioMed research international*. 2019;2019.
28. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. *Clinical Pharmacology & Therapeutics*. 2010;87(4):483-7.
29. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. *Nature reviews Clinical oncology*. 2012;9(3):135.
30. Bazick HS, Chang D, Mahadevappa K, Gibbons FK, Christopher KB. Red cell distribution width and all cause mortality in critically ill patients. *Critical care medicine*. 2011;39(8):1913.
31. Zhu M, Han M, Xiao X, Lu S, Guan Z, Song Y, et al. Dynamic Differences Of Red Cell Distribution Width Levels Contribute To The Differential Diagnosis Of Hepatitis B Virus-related Chronic Liver Diseases: A Case-control Study. *International Journal of Medical Sciences*. 2019;16(5):720.
32. Rezaeetalab, F., Mozdourian, M., Amini, M., Javidarabshahi, Z., Akbari, F. COVID-19: A New Virus as a Potential Rapidly Spreading in the Worldwide. *Journal of Cardio-Thoracic Medicine*, 2020; 8(1): 563-564